Palisade Bio, Inc. (PALI) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
The consensus price target is $1.50, representing a downside of 27.2% from the current price $2.06.
Analysts estimate Earnings Per Share (EPS) of $-11.66 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.48 vs est $-11.66 (beat +78.7%). 2025: actual $-0.30 vs est $-0.54 (beat +44.9%). Analyst accuracy: 0%.
PALI Stock — 12-Month Price Forecast
$1.50
▼ -27.18% Downside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for Palisade Bio, Inc., the price target is $1.50.
The average price target represents a -27.18% change from the last price of $2.06.
PALI Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to Palisade Bio, Inc. in the past 3 months
EPS Estimates — PALI
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.48
vs Est –$11.66
▲ 370.3% off
2025
Actual –$0.30
vs Est –$0.54
▲ 81.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — PALI
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
